[go: up one dir, main page]

NO996133L - Oil-in-water vaccine formulations - Google Patents

Oil-in-water vaccine formulations

Info

Publication number
NO996133L
NO996133L NO996133A NO996133A NO996133L NO 996133 L NO996133 L NO 996133L NO 996133 A NO996133 A NO 996133A NO 996133 A NO996133 A NO 996133A NO 996133 L NO996133 L NO 996133L
Authority
NO
Norway
Prior art keywords
oil
vaccine formulations
water
water vaccine
cmillions
Prior art date
Application number
NO996133A
Other languages
Norwegian (no)
Other versions
NO996133D0 (en
Inventor
Nathalie Garcon
Patricia Marie Christine Momin
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO996133D0 publication Critical patent/NO996133D0/en
Publication of NO996133L publication Critical patent/NO996133L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse vedrorer forbedrede stabile olje-i-vann-cmtilsjoncr som har en oljcdråpe-diameter på vesentlig 300-600 nm som omfatter triglyscrider og deres anvend- else som vaksineadj 11 vanter.The present invention relates to improved stable oil-in-water cmillions having an oil droplet diameter of substantially 300-600 nm comprising triglycerides and their use as vaccine adjuvants.

NO996133A 1997-06-11 1999-12-10 Oil-in-water vaccine formulations NO996133L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711990.3A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine
PCT/EP1998/003479 WO1998056414A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions

Publications (2)

Publication Number Publication Date
NO996133D0 NO996133D0 (en) 1999-12-10
NO996133L true NO996133L (en) 2000-01-26

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996133A NO996133L (en) 1997-06-11 1999-12-10 Oil-in-water vaccine formulations

Country Status (17)

Country Link
EP (1) EP0999852A1 (en)
JP (1) JP2002504106A (en)
KR (1) KR20010013644A (en)
CN (1) CN1260723A (en)
AR (1) AR012959A1 (en)
AU (1) AU728759B2 (en)
BR (1) BR9810614A (en)
CA (1) CA2293444A1 (en)
CO (1) CO4940401A1 (en)
GB (1) GB9711990D0 (en)
HU (1) HUP0004001A3 (en)
IL (1) IL133126A0 (en)
NO (1) NO996133L (en)
PL (1) PL337488A1 (en)
TR (1) TR199903048T2 (en)
WO (1) WO1998056414A1 (en)
ZA (1) ZA984969B (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
JP4812942B2 (en) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Enhancement of Neisseria antigen bactericidal activity using oligonucleotides containing CG motif
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
TR200103018T2 (en) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline Additive compounds containing immunostimulatory oligonucleotide and saponin.
ATE516046T1 (en) * 1999-05-13 2011-07-15 Wyeth Corp ADJUVANS COMBINATION FORMULATIONS
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
JP4540033B2 (en) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド Methods for inducing and / or enhancing immune responses against tumor antigens
EP1741782B1 (en) 2000-05-10 2011-06-22 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
DE60131670T2 (en) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Vaccines against cancer diseases
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20040241094A1 (en) * 2001-09-13 2004-12-02 Hesson Chung Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
JP4726485B2 (en) * 2002-08-02 2011-07-20 大日本住友製薬株式会社 Bacterial cell wall skeleton component formulation
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa METHODS OF VACCINATION AGAINST MALARIA
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1945252B1 (en) * 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
DK2384765T3 (en) 2005-12-22 2017-01-09 Glaxosmithkline Biologicals Sa Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
PL2043682T3 (en) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Influenza vaccine
JP5592110B2 (en) 2006-07-18 2014-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Malaria vaccine
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
PT2484375T (en) 2006-09-26 2018-07-09 Infectious Disease Res Inst Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA2668405C (en) 2006-11-03 2015-05-05 Schering-Plough Ltd. Canine lyme disease vaccine
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
AR066405A1 (en) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa VACCINE
PL2167121T3 (en) 2007-06-26 2016-01-29 Glaxosmithkline Biologicals Sa Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JP5508266B2 (en) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
EA201500910A1 (en) 2009-02-10 2016-04-29 Новартис Аг VACCINES AGAINST FLU WITH REDUCED NUMBER OF SQUALES
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
HRP20161585T1 (en) 2009-06-05 2016-12-30 Infectious Disease Research Institute SYNTHETIC GLUCOPYRANOSIL LIPIDES AS ADVANCE AND VACCINATION PREPARATIONS CONTAINING THEM
CN102596243B (en) 2009-06-16 2015-10-21 密执安大学评议会 Nanoemulsion vaccines
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and improved methods of making the same
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
MX2012011189A (en) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Hiv vaccine.
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
EP2621528A1 (en) 2010-09-27 2013-08-07 GlaxoSmithKline Biologicals S.A. Vaccine
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012092934A1 (en) 2011-01-06 2012-07-12 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PT2758432T (en) 2011-09-16 2019-06-14 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
DK2811981T3 (en) 2012-02-07 2019-06-11 Infectious Disease Res Inst IMPROVED ADMINISTRATION FORMATS CONTAINING TLR4 AGONISTS AND PROCEDURE FOR USE THEREOF
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2877207A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
AU2013295014B2 (en) 2012-07-24 2018-01-18 Sanofi Pasteur Vaccine compositions
WO2014066663A1 (en) 2012-10-24 2014-05-01 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
US10357554B2 (en) 2013-11-11 2019-07-23 The United States Of America, As Represented By The Secretary Of The Army AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
CA2929126C (en) 2013-11-13 2020-01-07 University Of Oslo Outer membrane vesicles and uses thereof
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial vaccine formulations
AU2015209575A1 (en) 2014-01-21 2016-07-21 Immune Design Corp. Compositions for use in the treatment of allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102547A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CN107530416A (en) 2015-03-05 2018-01-02 西北大学 Non-neuroinvasive viruses and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
KR102799265B1 (en) 2016-03-14 2025-04-23 유니버시티에트 이 오슬로 Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
EP3504230A1 (en) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
BE1024774B1 (en) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa COMPOSITIONS AND METHODS OF TREATMENT
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR20240096685A (en) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 Nanostructured lipid carriers and stable emulsions and uses thereof
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020013553A (en) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides.
JP2021533162A (en) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
JP2022524007A (en) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Hepatitis B immunization regimen and composition
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN120456919A (en) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 Hepatitis B composition
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
AU8336598A (en) 1998-12-30
GB9711990D0 (en) 1997-08-06
AU728759B2 (en) 2001-01-18
CN1260723A (en) 2000-07-19
CO4940401A1 (en) 2000-07-24
KR20010013644A (en) 2001-02-26
HUP0004001A2 (en) 2001-03-28
PL337488A1 (en) 2000-08-28
NO996133D0 (en) 1999-12-10
AR012959A1 (en) 2000-11-22
JP2002504106A (en) 2002-02-05
EP0999852A1 (en) 2000-05-17
CA2293444A1 (en) 1998-12-17
HUP0004001A3 (en) 2001-07-30
TR199903048T2 (en) 2000-08-21
BR9810614A (en) 2000-09-12
IL133126A0 (en) 2001-03-19
WO1998056414A1 (en) 1998-12-17
ZA984969B (en) 1999-12-09

Similar Documents

Publication Publication Date Title
NO996133L (en) Oil-in-water vaccine formulations
DK1417211T3 (en) Natural marine phospholipids containing flavonoids and polyunsaturated phospholipids and their use
PA8443001A1 (en) PREVENTION OF LOSS AND RESTORATION OF THE BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS
DE60210456D1 (en) SOLUBIZATION OF CAPSULES POLYSACCHARIDEN
ES2195970T3 (en) L-RIBAVIRINA AND USES OF THE SAME.
DK0988292T3 (en) Piperazine derivatives and their use as anti-inflammatory agents
AR030829A1 (en) A FORMATION OF VACCINE, PROCEDURE FOR THE PRODUCTION OF THE SAME, USE OF SUCH PREPARATION AND A CASE FOR ADMINISTRATION VIA INTRANASAL
ES2058185T3 (en) DERIVATIVES OF CAMPTOTECINA AND PROCEDURE FOR ITS PREPARATION.
ES2178291T3 (en) USE OF 3-BENZOIL-ACETIC, ESTER, OR AMIDAS ACIDS FOR THE TREATMENT OF GLCUCA GLAUCOMA.
NO985981D0 (en) Insulin preparations containing NaCl
DE60218919D1 (en) Transparent microemulsions with high oil content
HUP0001090A2 (en) Sulphonylurea and/adjuvant based solid mixtures
BR0114912A (en) Kahalalide f
DK1056462T3 (en) Use of rhamnolipids as cosmetics
DE60207577D1 (en) softener
BR0011174A (en) Compositions, compounds, isolated compounds and methods to control pests
AU3384601A (en) Arch structure
BR0008382A (en) Controlled release formulation for copd treatment
ATE201680T1 (en) 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE ACID ADDITION SALTS
EA200400412A1 (en) HERBICIDE COMPOSITION
GT199900113A (en) FKBP INHIBITORS.
TR200101968T2 (en) The use of citric acid derivatives as an aid in drugs used against pests.
ES2128191T3 (en) COMPOSITIONS FOR DYEING BY OXIDATION OF KERATIN FIBERS AND DYEING PROCEDURE USING THEM.
ES2189206T3 (en) BETA-ALCOXIACRYLATES AGAINST MALARIA.
DK1163248T3 (en) 1,5-anhydro-D-fructose substituted with a hydrophobic group for use as an antioxidant and / or emulsifier

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application